InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Moves Forward to Strengthen the Case for HyBryte(TM)
April 29, 2025
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company, is advancing its phase 3 replication study (“FLASH2”) for HyBryte(TM), a novel photodynamic therapy designed to treat early-stage cutaneous T-cell lymphoma (“CTCL”). Building on the success of a prior phase 3 trial, HyBryte(TM)—which uses synthetic hypericin activated by safe visible light—offers a potentially game-changing approach by providing a […]
InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Featured in Benzinga Video Highlighting 75% HyBryte™ Response Rate in FDA-Backed Skin Cancer Trial
April 25, 2025
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on rare diseases, is featured in a new Benzinga video detailing clinical progress for its lead candidate HyBryte™, which achieved a 75% response rate in a trial for cutaneous T-cell lymphoma (CTCL), a rare form of skin cancer. The trial is supported by funding from a U.S. […]
Soligenix Inc. (NASDAQ: SNGX) Advances CiVax Amid Ongoing COVID-19 Threat
April 21, 2025
Despite the passage of time since the pandemic, COVID-19 continues to pose a significant global health threat. Recent data from the World Health Organization (“WHO”) indicates that during the 28-day period from Jan. 6 to Feb. 2, 2025, more than 147,000 new COVID-19 cases were reported globally, representing a 16% decrease compared to the previous period […]
InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Announces Positive Data, Continued Advancement of HyBryte(TM)
April 14, 2025
Soligenix (NASDAQ: SNGX) is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company today announced interim results from the ongoing open-label, investigator-initiated study (“IIS”) evaluating extended HyBryte(TM) (synthetic hypericin) treatment for up to 54 weeks in patients with early-stage cutaneous T-cell […]
Soligenix Inc. (NASDAQ: SNGX) Spotlighted in Recent Zacks Small-Cap Research Report, Earns a $35 Valuation
April 8, 2025
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company specializing in developing and commercializing products to treat rare diseases, has recently been the focus of a comprehensive analysis by Zacks Small-Cap Research (https://ibn.fm/OpnDo). The report supports a $35 per share valuation and provides an in-depth evaluation of Soligenix’s diverse product pipeline, financial health and strategic positioning within the […]
Soligenix Inc. (NASDAQ: SNGX) Advances Phase 3 Replication Study for Early-Stage Cutaneous T-Cell Lymphoma Treatment
April 3, 2025
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company specializing in the development and commercialization of treatments for rare diseases and unmet medical needs, is making significant strides in its efforts to bring innovative therapies to patients with early-stage cutaneous T-cell lymphoma (“CTCL”). The company’s lead candidate, HyBryte(TM) (“SGX301”), has already demonstrated positive results in a prior […]
InvestorNewsBreaks – Zacks Maintains $35.00 Price Per Share Valuation for Soligenix Inc. (NASDAQ: SNGX) Amid Promising Vaccine and CTCL Therapy Progress
March 28, 2025
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company targeting rare diseases, was spotlighted in a recent Zacks Small-Cap Research report that presented a favorable analysis, emphasizing the company’s advancements in vaccine and photodynamic therapy technologies. The study highlights promising preclinical data for CiVax(TM), a thermostabilized COVID-19 booster, which demonstrated broad immune protection in non-human primates. Zacks […]
InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Taps IBN to Lead Corporate Communications Strategy
March 25, 2025
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company targeting rare diseases, has selected IBN to manage its corporate communications and investor outreach. Soligenix is advancing late-stage clinical programs through its oncology and inflammation-focused Specialized BioTherapeutics segment and its Public Health Solutions division, which develops vaccines for biothreats such as ricin, Ebola, and Marburg. With support from […]
IBN Initiates Coverage of Soligenix Inc.
March 25, 2025
AUSTIN, Texas, March 25, 2025 (GLOBE NEWSWIRE) — via IBN – Soligenix Inc. (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases with an unmet medical need, has selected IBN, a multifaceted financial news and publishing company serving private and public entities, to spearhead its corporate communications efforts. Soligenix operates through two […]
InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Announces Key Milestones and 2024 Financial Results
March 21, 2025
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today announced its recent accomplishments and financial results for the year ended Dec. 31, 2024. “We remain highly focused on advancing our multiple clinical programs as we work towards achieving a […]
InvestorNewsBreaks – Why Soligenix Inc. (NASDAQ: SNGX) Is ‘One to Watch’
March 18, 2025
Soligenix (NASDAQ: SNGX) is a late-stage biopharmaceutical company focused on developing and commercializing treatments for rare diseases with high unmet medical needs. “Operating through two key segments, the company’s Specialized BioTherapeutics division is dedicated to oncology and inflammation therapies, while its Public Health Solutions segment advances vaccines and therapeutics targeting biothreats and infectious diseases,” reads […]
Soligenix Inc. (NASDAQ: SNGX) Is ‘One to Watch’
March 13, 2025
Soligenix (NASDAQ: SNGX) is a late-stage biopharmaceutical company focused on developing and commercializing treatments for rare diseases with high unmet medical needs. Operating through two key segments, the company’s Specialized BioTherapeutics division is dedicated to oncology and inflammation therapies, while its Public Health Solutions segment advances vaccines and therapeutics targeting biothreats and infectious diseases. The […]
InvestorNewsBreaks – Soligenix Inc. (SNGX) to Present HyBryte™ and SGX302 Data at Dermatology Conferences
March 6, 2025
Soligenix (SNGX), a late-stage biopharmaceutical company focused on rare diseases, announced that its lead investigators will present findings from recent trials on HyBryte™ for cutaneous T-cell lymphoma (CTCL) and SGX302 for mild-to-moderate psoriasis at the U.S. Cutaneous Lymphoma Consortium (USCLC) Workshop on March 6, 2025, and the American Academy of Dermatology (AAD) Annual Meeting from […]
Soligenix, Inc. (NASDAQ: SNGX) Featured in Coverage of Investor Summit Group’s Q1 Virtual Event
March 8, 2022
Soligenix (NASDAQ: SNGX) is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Their Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte(TM) (SGX301 or synthetic hypericin) as a novel photodynamic therapy utilizing safe visible light for the treatment […]
Roth Capital Partners to Virtually Host 10th Annual Roth Technology Event
November 15, 2021
Event to Feature One-on-One Meetings Between Institutional Investors and Senior Company Management from Select Companies across a Variety of Technology Sub-Sectors NEWPORT BEACH, Calif., Nov 15, 2021 — via InvestorWire — Roth Capital Partners (Roth), a full-service investment bank renowned for serving emerging growth companies today announces that it will host the 10th Annual Roth Technology […]
Roth Capital Partners Provides Agenda Details of Inaugural AgTech Answers Event
November 11, 2021
Event to Feature Fireside Chat, Industry Panel and One-on-One Meetings Between Institutional Investors and Senior Company Management NEWPORT BEACH, Calif., Nov 11, 2021 — via InvestorWire — Roth Capital Partners (Roth), a full-service investment bank renowned for serving emerging growth companies is pleased to announce the agenda for the Inaugural AgTech Answers Virtual Event. “AgTech […]
Soligenix Inc. (NASDAQ: SNGX) Featured in Virtual Coverage of the Fall Investor Summit 2020
November 16, 2020
Soligenix Inc. (NASDAQ: SNGX) is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Its Specialized BioTherapeutics business segment is developing SGX301 as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma, where it has demonstrated positive […]
77 Public Companies to present at the Virtual Fall Investor Summit on November 16th-18th
November 12, 2020
NEW YORK, Nov. 12, 2020 (GLOBE NEWSWIRE) — via InvestorWire — The Virtual Summer Summit will take place on November 16th-18th, connecting 77 presenting small and microcap companies with distinguished investors from around the globe. A full list of issuers are listed below along with webcasting links to view presentations. Company Ticker Webcast URL Actinium Pharmaceuticals ATNM […]